Russia enters the market of TB diagnosis services in Latin America

| |
0
209

In early August, the first lot of Russian-made diagnostic drug for detecting TB at early stages was delivered to Cuba.

The first supplies of Tuberculin manufactured by the Federal State Unitary Enterprise (FSUE) St. Petersburg Research Institute of Vaccines and Serums and the Bacterial Preparation Factory (SPbSRIVS) of the Russian Federal Biomedical Agency were successfully completed as part of further collaboration between the Russian enterprise and the Cuban Ministry of Health.

“This is certainly an important event both for us and the entire Latin America. Every day, 4400 people die of TB across the world and the early diagnosis is a recognized and effective way to fight this disease. Last weekend, the first lot of 54,000 doses of the diagnostic drug for TB detection manufactured by SPbSRIVS was delivered to Cuba. In the future, we expect that the supplies will expand to other Latin American countries,” said Victor Trukhin, the Director of SPbSRIVS.

The Latin American Institute of Biotechnology MECHNIKOV, a joint Russian-Nicaraguan venture for manufacturing immunobiological drugs, acted as a partner for supplies of Tuberculin. The supply logistics, including the compliance with the cold chain requirements, were provided by the experts of DHL International GmbH.

“The countries of the region, as well as the Pan American Health Organization (PAHO), show increasing interest in the Russian-made Tuberculin, because it was used for many years, and has proven efficacy and good cost-quality balance compared to foreign analogs,” said Stanislav Uyba, the General Director of MECHNIKOV Institute.

Isaltis Banner